Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Rare Tumours”

65 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 65 results

Testing effectiveness (Phase 2)Study completedNCT03108131
What this trial is testing

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Who this might be right for
Skin Squamous Cell CarcinomaAppendix AdenocarcinomaRare Lesion+9 more
M.D. Anderson Cancer Center 49
Testing effectiveness (Phase 2)Ended earlyNCT02938793
What this trial is testing

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Who this might be right for
CancerRare Disease
Prisma Health-Upstate 92
Testing effectiveness (Phase 2)Looking for participantsNCT07117890
What this trial is testing

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Non Small Cell Lung Cancer
Fudan University 34
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Not applicableLooking for participantsNCT06285500
What this trial is testing

Umbrella Study for Single Patient Treatments in Oncology

Who this might be right for
Advanced CancerRare Diseases
University Health Network, Toronto 400
Testing effectiveness (Phase 2)Study completedNCT05024968
What this trial is testing

Sintilimab in Cancer of Unknown Primary

Who this might be right for
Cancer of Unknown Primary Site
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT02269943
What this trial is testing

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Neoplasms
Celgene 36
Testing effectiveness (Phase 2)Looking for participantsNCT07309770
What this trial is testing

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Who this might be right for
Urachal CancerAdvanced Solid Tumor CancerAntibody-drug Conjugates
Sheng Zhang 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT04504071
What this trial is testing

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer
Shanghai Chest Hospital 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05142241
What this trial is testing

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Looking for participantsNCT05168566
What this trial is testing

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Teligene US 99
Testing effectiveness (Phase 2)Active Not RecruitingNCT05715281
What this trial is testing

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Who this might be right for
Advanced Rare Malignant Solid NeoplasmRare Malignant Solid NeoplasmRefractory Rare Malignant Solid Neoplasm
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Not applicableLooking for participantsNCT06855134
What this trial is testing

Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers

Who this might be right for
Rare Cancer
German Cancer Research Center 946
Large-scale testing (Phase 3)UnknownNCT04741438
What this trial is testing

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Who this might be right for
Sarcoma
Centre Leon Berard 96
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Not applicableUnknownNCT05411276
What this trial is testing

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

Who this might be right for
HER2 Mutant Non-small Cell Lung Cancer
Beijing Chest Hospital 15
Not applicableLooking for participantsNCT02906943
What this trial is testing

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

Who this might be right for
Breast CancerLung CancerColorectal Cancer+8 more
University Health Network, Toronto 10,000
Large-scale testing (Phase 3)UnknownNCT04951648
What this trial is testing

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Testing effectiveness (Phase 2)Study completedNCT04790409
What this trial is testing

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Lung Cancer
Zhejiang Cancer Hospital 21
Next Page
480